It has been just about 3 weeks since a very important announcement was made by Starpharma - in regards to maximum tolerated dosage of anti-cancer drug Dep Docetaxel not being reached
The longer it takes to reach MTD (maximum tolerated dosage), the more valuable this anti-cancer drug being developed by Starpharma becomes. Not only that - all the collaborations with big pharmas on drug conjugates using dendrimers become "gold". Those companies will be wanting to sign a deal sooner rather than later with Starpharma to lock in - before any of the competitors do.
Exciting times coming
Above is my opinion and not investment advice
SPL Price at posting:
83.0¢ Sentiment: Buy Disclosure: Held
